Celldex Therapeutics, Inc. — Director's Dealing 2016

Jun 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-06-08

Reporting Person: Elston George (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-08	Common Stock	A	10000	—	Acquired	28500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-08	Non-Qualified Stock Option (right to buy)	$4.72	A	15000	Acquired	2026-06-08	Common Stock (15000)	Direct

Footnotes

F1: On June 8, 2016, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.

F2: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F3: Such option vests in three equal annual installments beginning June 8, 2017.